Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 10/20 | 0.64 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.46 |
| ▸ | MTAP | Q13126 | 8/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5606527 | 1.00 | PNP (0.64) | PNPHPRT1MTAP | |
| SCHEMBL505709 | 1.00 | PNP (0.64) | PNPHPRT1MTAP | |
| Hydrochloric Acid SCHEMBL4830734 | 0.99 | PNP (0.63) | PNPHPRT1MTAP | |
| SCHEMBL7100238 | 0.87 | PNP (0.60) | PNPHPRT1MTAP | |
| SCHEMBL506019 | 0.87 | PNP (0.60) | PNPHPRT1MTAP | |
| SCHEMBL5606739 | 0.87 | PNP (0.60) | PNPHPRT1MTAP | |
| Hydrochloric Acid SCHEMBL4065724 | 0.86 | PNP (0.59) | PNPHPRT1MTAP | |
| SCHEMBL14156772 | 0.85 | PNP (0.58) | PNPMTAP | |
| SCHEMBL505864 | 0.83 | MTAP (0.60) | PNPHPRT1MTAP | |
| SCHEMBL505499 | 0.83 | HPRT1 (0.50) | PNPHPRT1MTAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170216272-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-08-03 | — | — | US | disclosed |
| US-9597347-B2 | Compositions for treating obesity and insulin resistance disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-03-21 | — | — | US | disclosed |
| EP-3031461-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | The President and Fellows of Harvard College (US) | 2016-06-15 | — | — | EP | disclosed |
| US-9241916-B2 | Cognitive performance with sirtuin activators | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-01-26 | — | — | US | disclosed |
| US-9241916-B2 | Cognitive performance with sirtuin activators | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150133396-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-05-14 | — | — | US | disclosed |
| US-8846724-B2 | Compositions for treating obesity and insulin resistance disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-09-30 | — | — | US | disclosed |
| US-8242171-B2 | Method for reducing the weight of a subject or inhibiting weight gain in a subject | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242171-B2 | Method for reducing the weight of a subject or inhibiting weight gain in a subject | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-08-14 | — | — | US | disclosed |
| US-20120135091-A1 | METHODS AND COMPOSITIONS FOR ENHANCING LIFESPAN INVOLVING SIRTUIN-MODULATING COMPOUNDS AND CHALCOGENIDES | US ARMY, SECRETARY OF THE ARMY | 2012-05-31 | — | — | US | disclosed |
| WO-2007008548-A2 | METHODS AND RELATED COMPOSITIONS FOR TREATING OR PREVENTING OBESITY, INSULIN RESISTANCE DISORDERS, AND MITOCHONDRIAL-ASSOCIATED DISORDERS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| US-20070014833-A1 | Treatment of eye disorders with sirtuin modulators | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | US | disclosed |
| US-20070014833-A1 | Treatment of eye disorders with sirtuin modulators | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | US | disclosed |
| WO-2007005453-A2 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-01-11 | — | — | WO | disclosed |
| WO-2006138418-A2 | IMPROVEMENT OF COGNITIVE PERFORMANCE WITH SIRTUIN ACTIVATORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006127987-A2 | TREATMENT OF EYE DISORDERS WITH SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006105403-A2 | TREATMENT OF EYE DISORDERS WITH SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006079021-A2 | USE OF SIRTUIN-ACTIVATING COMPOUNDS FOR TREATING FLUSHING AND DRUG INDUCED WEIGHT GAIN | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006076681-A2 | NOVEL COMPOSITIONS FOR PREVENTING AND TREATING NEURODEGENERATIVE AND BLOOD COAGULATION DISORDERS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| WO-2005065667-A2 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133396-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | FABP4, GPR119, SIRT1 | PNP 3921/4885HPRT1 4585/4885MTAP 3429/4885 |
| US-20170216272-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | FABP4, GPR119, SIRT1 | PNP 3921/4885HPRT1 4585/4885MTAP 3429/4885 |
| US-20070014833-A1 | Treatment of eye disorders with sirtuin modulators | SIRT1, SIRT2, SIRT3 | PNP 4397/4885HPRT1 2456/4885MTAP 4736/4885 |
| US-20120135091-A1 | METHODS AND COMPOSITIONS FOR ENHANCING LIFESPAN INVOLVING SIRTUIN-MODULATING COMPOUNDS AND CHALCOGENIDES | HSF1, SIRT1, SIRT2 | PNP 4175/4885HPRT1 4015/4885MTAP 2311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.